Investor's Business Daily on MSN
IDEXX tumbles following an 'impressive' report; can it shake pet-health challenges?
Idexx stock fell Monday despite beating fourth-quarter expectations and issuing strong guidance for 2026.
IDEXX Laboratories has named Michael Erickson as its next CEO, with the transition scheduled for May 2026. The company also introduced the ImageVue DR50 Plus, its most advanced AI powered veterinary ...
(Reuters) - IDEXX Laboratories lowered its annual sales forecast after missing quarterly estimates on Wednesday, as the animal diagnostic equipment maker expects a hit from a slowdown in veterinary ...
Idexx's Q3 adjusted EPS rose 12% to $2.79, beating the $2.68 consensus. Organic revenue grew 6%, driven by Companion Animal and Water segment gains. Live on Wednesday: Historic Summer Setup: 3 "Power ...
(Reuters) - IDEXX Laboratories raised its full-year profit and sales forecasts on Tuesday, betting on higher demand for its diagnostic tests and lab services as more pet owners visit veterinary ...
A new diagnostic imaging solution with a lower radiation dose than earlier iterations was launched at the 2026 Veterinary Meeting & Expo (VMX) in Orlando, Florida, by IDEXX. The ImageVue DR50 Plus ...
Dublin, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The "Veterinary Infectious Disease Diagnostics Market - A Global and Regional Analysis: Focus on Technology, Product, Animal Type, Infection Type, End user, ...
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced two major advancements in veterinary cancer diagnostics: the expansion of its IDEXX Cancer Dx™ ...
Idexx’s second quarter largely met our expectations, though we trimmed our assumptions for the full year as foreign exchange headwinds have gained strength since the beginning of 2022. However, our ...
Nov 1 (Reuters) - Animal health diagnostic services provider IDEXX Laboratories (IDXX.O), opens new tab cut its annual sales forecast, after missing third-quarter revenue estimates on Wednesday, hurt ...
Stifel analyst Jonathan D. Block reiterated a Hold rating on IDEXX Laboratories, Inc. IDXX, lowering the price target to $500 from $525. IDEXX is capturing market share across multiple modalities, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results